News & events

What's new

RSS
Jun 2023 (116) May 2023 (440) Apr 2023 (426) Mar 2023 (515) Feb 2023 (389) Jan 2023 (384) Dec 2022 (288) Nov 2022 (317) Oct 2022 (216) Sep 2022 (259) Aug 2022 (153) Jul 2022 (244) Jun 2022 (251)
Date Content
31/03/2023 Minutes: Minutes of the PRAC meeting 4-7 July 2022
31/03/2023 Human medicines European public assessment report (EPAR): Sotyktu, Deucravacitinib, Psoriasis, 24/03/2023, Additional monitoring, Authorised
31/03/2023 Human medicines European public assessment report (EPAR): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron), Dinutuximab beta, Neuroblastoma, 08/05/2017, Orphan, Additional monitoring, Exceptional circumstances, 14, Authorised
31/03/2023 European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting , Online, European Medicines Agency, Amsterdam, the Netherlands, from 03/03/2023 to 03/03/2023
31/03/2023 Herbal medicinal product: Fragariae folium, Fragariae folium, C: ongoing call for scientific data
31/03/2023 Scientific guideline: Guideline on Quality Aspects of Pharmaceutical Veterinary Medicines for administration via drinking water - Draft Annex on compatibility studies between veterinary medicinal products and biocidal products
31/03/2023 Newsletter: CTIS newsflash – 31 March 2023
31/03/2023 Agenda: Agenda - Union Product Database – Volume of sales webinar for UPD industry users
31/03/2023 Human medicines European public assessment report (EPAR): Dzuveo, sufentanil citrate, Pain, 25/06/2018, 6, Authorised
31/03/2023 Other: European Medicines Agency guidance for applicants seeking access to PRIME scheme
31/03/2023 Other: European Medicines Agency guidance to support the preparation of the PRIME kick-off meeting and submission readiness meeting
31/03/2023 Template or form: PRIME regulatory roadmap and product development tracker
31/03/2023 Human medicines European public assessment report (EPAR): DuoPlavin, clopidogrel, Acetylsalicylic acid, Acute Coronary Syndrome; Myocardial Infarction, 14/03/2010, 29, Authorised
31/03/2023 News and press releases: Regulatory information – adjusted fees for applications to EMA from 1 April 2023
31/03/2023 Other: Explanatory note on general fees payable to the European Medicines Agency as of 1 April 2023
31/03/2023 Regulatory and procedural guideline: Rules for the implementation of Council Regulation (EC) No 297/95 on fees payable to the European Medicines Agency and other measures - Revised implementing rules to the Fee Regulation as of 1 April 2023
31/03/2023 Minutes: Minutes of the PRAC meeting 24-27 October 2022
31/03/2023 Minutes: Minutes of the PRAC meeting 7-10 June 2022
31/03/2023 Human medicines European public assessment report (EPAR): Lydisilka, estetrol monohydrate, drospirenone, Contraceptives, Oral, 19/05/2021, 3, Authorised
31/03/2023 Human medicines European public assessment report (EPAR): Capecitabine Medac, capecitabine, Colorectal Neoplasms, 19/11/2012, Generic, 13, Authorised
31/03/2023 Human medicines European public assessment report (EPAR): Kisqali, ribociclib succinate, Breast Neoplasms, 22/08/2017, 13, Authorised
31/03/2023 Other: Annex to interim measures regarding notification of pharmacovigilance alerts by marketing authorisation holders under Regulation (EU) 2019/6: contact points
31/03/2023 Human medicines European public assessment report (EPAR): Brintellix, Vortioxetine, Depressive Disorder, Major, 18/12/2013, 21, Authorised
31/03/2023 Human medicines European public assessment report (EPAR): Drovelis, drospirenone, estetrol monohydrate, Contraceptives, Oral, 19/05/2021, 4, Authorised
31/03/2023 Human medicines European public assessment report (EPAR): Blenrep, belantamab mafodotin, Multiple Myeloma, 25/08/2020, Orphan, Additional monitoring, Conditional approval, 5, Authorised
31/03/2023 Herbal medicinal product: Malvae folium, Malvae folium, C: ongoing call for scientific data
31/03/2023 Human medicines European public assessment report (EPAR): Grasustek, pegfilgrastim, Neutropenia, 20/06/2019, Additional monitoring, Biosimilar, 4, Authorised
31/03/2023 Herbal - Call for data: Call for scientific data for the periodic review of the monograph on Malvae folium
31/03/2023 Human medicines European public assessment report (EPAR): Mycamine, micafungin, Candidiasis, 25/04/2008, 18, Authorised
31/03/2023 News and press releases: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27 - 30 March 2023
31/03/2023 Summary of opinion: Wegovy , semaglutide, 30/03/2023, Positive
31/03/2023 Summary of opinion: Briumvi, ublituximab, 30/03/2023, Positive
31/03/2023 Summary of opinion: Ultomiris, ravulizumab, 30/03/2023, Positive
31/03/2023 Summary of opinion: Entresto, sacubitril, valsartan, 30/03/2023, Positive
31/03/2023 Summary of opinion: Ultomiris, ravulizumab, 30/03/2023, Positive
31/03/2023 Summary of opinion: Neparvis, sacubitril, valsartan, 30/03/2023, Positive
31/03/2023 Summary of opinion: Sugammadex Adroiq, sugammadex, 30/03/2023, Positive
31/03/2023 Summary of opinion: Qaialdo, spironolactone, 30/03/2023, Positive
31/03/2023 Withdrawn application: Feraheme, ferumoxytol, Date of withdrawal: 09/03/2023, Initial authorisation
31/03/2023 Human medicines European public assessment report (EPAR): Kesimpta, Ofatumumab, Multiple Sclerosis, Relapsing-Remitting, 26/03/2021, Additional monitoring, 6, Authorised
31/03/2023 Herbal medicinal product: Soiae oleum raffinatum, Soiae oleum raffinatum, C: ongoing call for scientific data
31/03/2023 Herbal medicinal product: Malvae sylvestris flos, Malvae sylvestris flos, C: ongoing call for scientific data
31/03/2023 Herbal - Call for data: Call for scientific data for the periodic review of the monograph on Malvae sylvestris flos
31/03/2023 Herbal - Call for data: Call for scientific data for the periodic review of the monograph on Soiae oleum raffinatum
31/03/2023 Herbal - Call for data: Call for scientific data for the periodic review of the monograph on Matricariae aetheroleum
31/03/2023 Herbal medicinal product: Matricariae aetheroleum, Matricariae aetheroleum, C: ongoing call for scientific data
31/03/2023 Newsletter: Big Data highlights - Issue 5
31/03/2023 Herbal medicinal product: Lecithinum ex soya, Lecithinum ex soya, C: ongoing call for scientific data
31/03/2023 Herbal - Call for data: Call for scientific data for the periodic review of the monograph on Lecithinum ex soya - Revision 1
31/03/2023 Herbal - Call for data: Call for scientific data for the periodic review of the monograph on Fragariae folium - Revision 1
30/03/2023 Herbal medicinal product: Juniperi galbulus (pseudo-fructus), Juniperi galbulus (pseudo-fructus), F: Assessment finalised
30/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Verquvo, Vericiguat, PM: decision on the application for modification of an agreed PIP, P/0454/2022
30/03/2023 News and press releases: EMA recommends approval of Bimervax as a COVID-19 booster vaccine
30/03/2023 Human medicines European public assessment report (EPAR): Dasatinib Accord, dasatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 24/03/2022, Generic, 1, Withdrawn
30/03/2023 Human medicines European public assessment report (EPAR): Dasatinib Accordpharma, dasatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 24/03/2022, Generic, 1, Withdrawn
30/03/2023 Public information on medicine shortages
30/03/2023 Quarterly system demo - Q1 2023 , Online, 09:00 - 13:00 Amsterdam time (CET), from 22/03/2023 to 22/03/2023
30/03/2023 Minutes: Meeting Summary of the Medicine Shortages (SPOC) Working Party 15 February 2023
30/03/2023 Minutes: Meeting Summary of the Medicine Shortages (SPOC) Working Party 18 January 2023
30/03/2023 Minutes: Meeting Summary of the Medicine Shortages (SPOC) Working Party 13 December 2022
30/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Givinostat, PM: decision on the application for modification of an agreed PIP, P/0513/2022
30/03/2023 Other: Records of data processing for Data Analysis and Real World Interrogation Network (DARWIN EU®)
30/03/2023 Human medicines European public assessment report (EPAR): HyQvia, Human normal immunoglobulin, Immunologic Deficiency Syndromes, 16/05/2013, 19, Authorised
30/03/2023 Human medicines European public assessment report (EPAR): Cibinqo, Abrocitinib, Dermatitis, Atopic, 09/12/2021, Patient safety, Additional monitoring, 3, Authorised
30/03/2023 Human medicines European public assessment report (EPAR): Xeljanz, Tofacitinib, Arthritis, Rheumatoid, 22/03/2017, 25/04/2013, Patient safety, 26, Authorised
30/03/2023 Direct healthcare professional communication (DHPC): Updated recommendations to minimise the risks of malignancy, major adverse cardiovascular events, serious infections, venous thromboembolism and mortality with use of Janus kinase inhibitors (JAKi), Active substance: Abrocitinib, filgotinib, Baricitinib, upadacitinib, Tofacitinib, DHPC type: Referral - Article 20 procedure, Last updated: 30/03/2023
29/03/2023 Human medicines European public assessment report (EPAR): Tepadina, thiotepa, Hematopoietic Stem Cell Transplantation, 15/03/2010, 19, Authorised
29/03/2023 Report: HMPC meeting report on European Union herbal monographs, guidelines and other activities - 13-15 March 2023
29/03/2023 Agenda: Agenda of the PDCO meeting 28-31 March 2023
29/03/2023 Human medicines European public assessment report (EPAR): Kineret, anakinra, Arthritis, Rheumatoid; COVID-19 virus infection, 08/03/2002, 33, Authorised
29/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Xofluza, Baloxavir marboxil, PM: decision on the application for modification of an agreed PIP, P/0486/2021
29/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Vitrakvi, Larotrectinib, PM: decision on the application for modification of an agreed PIP, P/0487/2021
29/03/2023 Human medicines European public assessment report (EPAR): Azacitidine Accord, azacitidine, Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute, 13/02/2020, Generic, 6, Authorised
29/03/2023 Human medicines European public assessment report (EPAR): Imvanex, modified vaccinia Ankara - Bavarian Nordic (MVA-BN) virus, Smallpox Vaccine; Monkeypox virus, 31/07/2013, Additional monitoring, Exceptional circumstances, 25, Authorised
29/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Tabelecleucel, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0490/2020
29/03/2023 Human medicines European public assessment report (EPAR): Alecensa, alectinib hydrochloride, Carcinoma, Non-Small-Cell Lung, 16/02/2017, Additional monitoring, 14, Authorised
29/03/2023 Other: Network ICT Advisory Committee (NICTAC) - List of nominated members
29/03/2023 Human medicines European public assessment report (EPAR): Sancuso, granisetron, Vomiting; Cancer, 20/04/2012, 14, Authorised
29/03/2023 Human medicines European public assessment report (EPAR): Otezla, apremilast, Arthritis, Psoriatic; Psoriasis, 15/01/2015, 20, Authorised
29/03/2023 Human medicines European public assessment report (EPAR): Puregon, follitropin beta, Infertility; Hypogonadism, 02/05/1996, 34, Authorised
29/03/2023 Human medicines European public assessment report (EPAR): Tecovirimat SIGA, Tecovirimat, Poxviridae Infections; Cowpox; Monkeypox; Vaccinia; Smallpox, 06/01/2022, Additional monitoring, 1, Authorised
29/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Cyclophosphamide, PM: decision on the application for modification of an agreed PIP, P/0490/2021
29/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Flucelvax Tetra, Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1),Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2),Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Yamagata lineage),Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage) [QIVc], PM: decision on the application for modification of an agreed PIP, P/0492/2021
29/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Soticlestat, PM: decision on the application for modification of an agreed PIP, P/0491/2021
29/03/2023 Orphan designation: Iodine (131I) iobenguane for the: Treatment of neuroblastoma, 31/01/2008, Positive
29/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Nuvaxovid, Severe acute respiratory syndrome coronavirus 2 recombinant spike protein nanoparticle vaccine/ matrix-M1 adjuvant (NVX-CoV2373), PM: decision on the application for modification of an agreed PIP, P/0483/2021
29/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Deferoxamine (mesylate),histidine,tryptophan,aspartic acid,n-acetyl-histidine (monohydrate),glycine,alpha-ketoglutaric acid,arginine,potassium chloride,magnesium chloride (hexahydrate),calcium chloride (dihydrate),sodium chloride,alanine,3,4-dimethoxy-N-methylbenzohydroxamic acid (Custodiol-N), PM: decision on the application for modification of an agreed PIP, P/0484/2021
29/03/2023 Human medicines European public assessment report (EPAR): Azopt, brinzolamide, Glaucoma, Open-Angle; Ocular Hypertension, 09/03/2000, 28, Authorised
29/03/2023 Human medicines European public assessment report (EPAR): Glivec, imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma; Gastrointestinal Stromal Tumors; Dermatofibrosarcoma; Myelodysplastic-Myeloproliferative Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hypereosinophilic Syndrome, 07/11/2001, Additional monitoring, 45, Authorised
29/03/2023 Human medicines European public assessment report (EPAR): Sivextro, tedizolid phosphate, Soft Tissue Infections; Skin Diseases, Bacterial, 23/03/2015, 21, Authorised
29/03/2023 Human medicines European public assessment report (EPAR): Nyvepria, pegfilgrastim, Neutropenia, 18/11/2020, Additional monitoring, Biosimilar, 5, Authorised
29/03/2023 Human medicines European public assessment report (EPAR): Eucreas, vildagliptin, metformin hydrochloride, Diabetes Mellitus, Type 2, 14/11/2007, 23, Authorised
29/03/2023 Human medicines European public assessment report (EPAR): Memantine Mylan, memantine hydrochloride, Alzheimer Disease, 21/04/2013, Generic, 10, Authorised
29/03/2023 Human medicines European public assessment report (EPAR): Mimpara, cinacalcet hydrochloride, Hypercalcemia; Parathyroid Neoplasms; Hyperparathyroidism, 22/10/2004, 25, Authorised
29/03/2023 Human medicines European public assessment report (EPAR): Arsenic trioxide Mylan, Arsenic trioxide, Leukemia, Promyelocytic, Acute, 01/04/2020, Generic, 4, Authorised
29/03/2023 Report: Key performance indicators (KPIs) to monitor the European clinical trials environment (1-28 February 2023, edition 11)
29/03/2023 Referral: Pholcodine-containing medicinal products , pholcodine, Article 107i procedures, European Commission final decision, 14/12/2022, 06/03/2023, 29/03/2023
28/03/2023 Other: Nominations to the Network Portfolio Advisory Group
28/03/2023 Network Portfolio
28/03/2023 Other: Questions and answers on describing adverse events in the product information (summary of product characteristics (SPC) and package leaflet (PL))
28/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Dupixent, dupilumab, W: decision granting a waiver in all age groups for all conditions or indications, P/0121/2021
28/03/2023 Human medicines European public assessment report (EPAR): Deferasirox Mylan, deferasirox, Iron Overload; beta-Thalassemia, 26/09/2019, Generic, 9, Authorised
28/03/2023 Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Urologic Neoplasms; Mesothelioma; Colorectal Neoplasms, 19/06/2015, 52, Authorised
28/03/2023 News and press releases: DARWIN EU® has completed its first studies and is calling for new data partners
28/03/2023 Data Analysis and Real World Interrogation Network (DARWIN EU)
28/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Aimovig, erenumab, PM: decision on the application for modification of an agreed PIP, P/0475/2021
28/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Cresemba, Isavuconazonium sulfate, PM: decision on the application for modification of an agreed PIP, P/0479/2021
28/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Vaxzevria (previously COVID-19 Vaccine AstraZeneca), COVID-19 vaccine (ChAdOx1-S [recombinant]) (AZD1222), PM: decision on the application for modification of an agreed PIP, P/0559/2021
28/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Breyanzi, Lisocabtagene maraleucel, PM: decision on the application for modification of an agreed PIP, P/0558/2021
28/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Lydisilka, Estetrol,drospirenone, PM: decision on the application for modification of an agreed PIP, P/0561/2021
28/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Palovarotene, PM: decision on the application for modification of an agreed PIP, P/0562/2021
28/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Fully human IgG1 RB-1 YTE anti-RSV F monoclonal antibody (MK-1654), PM: decision on the application for modification of an agreed PIP, P/0554/2021
28/03/2023 Other: MedDRA Important medical event terms list - version 26.0
27/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Glycopyrronium bromide, PM: decision on the application for modification of an agreed PIP, P/0565/2021
27/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Bavencio, avelumab, PM: decision on the application for modification of an agreed PIP, P/0546/2021
27/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Comirnaty, Tozinameran, PM: decision on the application for modification of an agreed PIP, P/0547/2021
27/03/2023 Other: Records of data processing activity relating to staff engagement surveys (public)
27/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Synthetic double-stranded siRNA oligonucleotide directed against lactate dehydrogenase A mRNA and containing four modified nucleosides which form a ligand cluster of four N-acetylgalactosamine residues (DCR-PHXC), PM: decision on the application for modification of an agreed PIP, P/0541/2021
27/03/2023 ICH Guideline Q5A(R2) on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin - Scientific guideline
27/03/2023 Orphan designation: edaravone for the: Treatment of amyotrophic lateral sclerosis, 16/12/2014, Positive
27/03/2023 Fifth EMA-EFPIA annual bilateral meeting , Hybrid, 14:00 - 16:00 Amsterdam time (CET), from 07/02/2023 to 07/02/2023
27/03/2023 Herbal medicinal product: Hippocastani cortex, Hippocastani cortex, F: Assessment finalised
27/03/2023 Report: List of withdrawn medicinal products in accordance with Art. 123(4) of the Directive (1 January - 31 December 2022)
27/03/2023 Other: About us - European Medicines Agency (EMA)
27/03/2023 Orphan designation: Recombinant adeno-associated viral vector containing the human RPGR gene for the: Treatment of retinitis pigmentosa caused by mutations in the RPGR gene, 30/05/2016, Positive
27/03/2023 Orphan designation: (S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidine-3-yl)chroman-2-carboxamide hydrochloride for the: Treatment of maternally-inherited diabetes and deafness, 28/06/2019, Positive
27/03/2023 Orphan designation: (S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride for the: Treatment of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes, 10/08/2015, Positive
27/03/2023 Orphan designation: (S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride for the: Treatment of Leigh syndrome, 15/10/2014, Positive
27/03/2023 Human medicines European public assessment report (EPAR): Nuvaxovid, SARS-CoV-2 recombinant spike protein, COVID-19 virus infection, 20/12/2021, Additional monitoring, Conditional approval, 8, Authorised
27/03/2023 Direct healthcare professional communication (DHPC): Pholcodine-containing medicinal products no longer available on the EU market, Active substance: pholcodine, DHPC type: Referral - Article 107i procedure, Last updated: 27/03/2023
27/03/2023 Orphan designation: Autologous CD34+ cells transfected with lentiviral vector containing the Wiskott-Aldrich syndrome protein gene (etuvetidigene autotemcel) for the: Treatment of Wiskott-Aldrich syndrome, 06/06/2012, Positive
27/03/2023 Orphan designation: Adeno-associated viral vector serotype LK03 encoding human ornithine transcarbamylase for the: Treatment of ornithine transcarbamylase deficiency, 20/03/2017, Positive
24/03/2023 Fourth Industry Standing Group (ISG) meeting , Online, from 21/03/2023 to 21/03/2023
24/03/2023 Referral procedures: human medicines
24/03/2023 Human medicines European public assessment report (EPAR): Imraldi, adalimumab, Spondylitis, Ankylosing; Arthritis, Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Hidradenitis Suppurativa; Arthritis, 24/08/2017, Biosimilar, 20, Authorised
24/03/2023 Human medicines European public assessment report (EPAR): Comirnaty, Single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2, COVID-19 virus infection, 21/12/2020, Patient safety, Additional monitoring, 41, Authorised
24/03/2023 Summary of opinion: Newflend ND H9, turkey herpes virus, strain rHVT/ND expressing Newcastle disease virus, live, 23/03/2023, Positive
24/03/2023 News and press releases: Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 21-22 March 2023
24/03/2023 Human medicines European public assessment report (EPAR): Xromi, hydroxycarbamide, Anemia, Sickle Cell, 01/07/2019, 6, Authorised
24/03/2023 Human medicines European public assessment report (EPAR): Symkevi, tezacaftor, ivacaftor, Cystic Fibrosis, 31/10/2018, Orphan, Additional monitoring, 11, Authorised
24/03/2023 Human medicines European public assessment report (EPAR): Giapreza, Angiotensin II acetate, Hypotension; Shock, 23/08/2019, Additional monitoring, 3, Authorised
24/03/2023 Human medicines European public assessment report (EPAR): Opsumit, Macitentan, Hypertension, Pulmonary, 20/12/2013, Orphan, 22, Authorised
24/03/2023 Human medicines European public assessment report (EPAR): Kanjinti, trastuzumab, Stomach Neoplasms; Breast Neoplasms, 16/05/2018, Biosimilar, 10, Authorised
24/03/2023 Handling competing interests
24/03/2023 Other: Fergus Sweeney - Assessment outcome of occupational activities after leaving the service (March 2023)
24/03/2023 Other: Agnes Saint-Raymond - Assessment outcome of occupational activities after leaving the service (March 2023)
24/03/2023 Human medicines European public assessment report (EPAR): Levetiracetam Accord, levetiracetam, Epilepsy, 03/10/2011, Generic, 15, Authorised
24/03/2023 Human medicines European public assessment report (EPAR): Bavencio, avelumab, Neuroendocrine Tumors, 18/09/2017, Additional monitoring, 15, Authorised
24/03/2023 Other: Acceptability of IU as abbreviation for International Units in the strength of human medicinal products
24/03/2023 Orphan designation: Soluble recombinant human fibroblast growth factor receptor 3 for the: Treatment of achondroplasia, 27/02/2017, Withdrawn
24/03/2023 Human medicines European public assessment report (EPAR): Zokinvy, Lonafarnib, Progeria; Laminopathies, 18/07/2022, Orphan, Additional monitoring, Exceptional circumstances, 1, Authorised
24/03/2023 Other: European Union herbal monographs: Overview of recommendations for the uses of herbal medicinal products in the paediatric population
24/03/2023 Human medicines European public assessment report (EPAR): Taxotere, docetaxel, Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Prostatic Neoplasms; Stomach Neoplasms; Breast Neoplasms, 27/11/1995, 50, Authorised
24/03/2023 Human medicines European public assessment report (EPAR): Myocet liposomal (previously Myocet), doxorubicin hydrochloride, Breast Neoplasms, 13/07/2000, 24, Authorised
24/03/2023 Orphan designation: miglustat for the: Treatment of glycogen storage disease type II (Pompe's disease), 11/01/2019, Withdrawn
24/03/2023 Human medicines European public assessment report (EPAR): Enspryng, satralizumab, Neuromyelitis Optica, 24/06/2021, Orphan, 2, Authorised
24/03/2023 Human medicines European public assessment report (EPAR): Tamiflu, oseltamivir, Influenza, Human, 20/06/2002, 42, Authorised
24/03/2023 Human medicines European public assessment report (EPAR): Miglustat Dipharma, miglustat, Gaucher Disease, 18/02/2019, Generic, 5, Authorised
24/03/2023 Other: HMPC meetings in 2025 and 2026
24/03/2023 Human medicines European public assessment report (EPAR): Brukinsa, zanubrutinib, Waldenstrom Macroglobulinemia, 22/11/2021, Additional monitoring, 5, Authorised
24/03/2023 Cancer Medicines Forum: June 2022 , Online, from 28/06/2022 to 28/06/2022
24/03/2023 Cancer Medicines Forum: kick-off meeting , Online, 08:30 - 12:30 Amsterdam time (CEST), from 31/03/2022 to 31/03/2022
24/03/2023 Cancer Medicines Forum: December 2022 , Online, from 20/12/2022 to 20/12/2022
23/03/2023 Referral procedures: veterinary medicines
23/03/2023 EIC / EMA Info Day: Regulatory support for the development of innovative medicines and technologies , Online, 09:00 - 12:30 Amsterdam time (CET), from 31/01/2023 to 31/01/2023
23/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Censavudine, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0103/2022
23/03/2023 Orphan designation: Adeno-associated viral vector serotype 2 containing the human SLC6A3 gene for the: Treatment of dopamine transporter deficiency syndrome, 13/01/2023, Positive
23/03/2023 Orphan designation: Autologous CD34+ cells transduced with a lentiviral vector encoding the human NCF1 gene for the: Treatment of chronic granulomatous disease, 13/01/2023, Positive
23/03/2023 Orphan designation: Efzofitimod for the: Treatment of sarcoidosis, 13/01/2023, Positive
23/03/2023 Orphan designation: Opelconazole for the: Treatment of invasive aspergillosis, 13/01/2023, Positive
23/03/2023 Orphan designation: Autologous hematopoietic cells genetically modified with a lentiviral vector containing the human RAG2 gene for the: Treatment of recombination-activating gene 2 deficient severe combined immunodeficiency, 13/01/2023, Positive
23/03/2023 Orphan designation: Nanatinostat, Valganciclovir for the: Treatment of diffuse large B-cell lymphoma, 13/01/2023, Positive
23/03/2023 Orphan designation: Retifanlimab for the: Treatment of Merkel cell carcinoma, 13/01/2023, Positive
23/03/2023 Orphan designation: N1,N14-diethyl-3S,12S-dihydroxyhomospermine tetrahydrochloride for the: Treatment of pancreatic cancer, 13/01/2023, Positive
23/03/2023 Orphan designation: Octreotide acetate for the: Treatment of carcinoid syndrome, 13/01/2023, Positive
23/03/2023 Orphan designation: 3-(1-(2',3'-dimethoxy-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazol-4-yl)benzoic acid for the: Treatment of Duchenne muscular dystrophy, 13/01/2023, Positive
23/03/2023 Orphan designation: Vorasidenib hemicitrate hemihydrate for the: Treatment of glioma, 13/01/2023, Positive
23/03/2023 Human medicines European public assessment report (EPAR): Truvelog Mix 30, insulin aspart, Diabetes Mellitus, 25/04/2022, Additional monitoring, Biosimilar, 1, Authorised
23/03/2023 Human medicines European public assessment report (EPAR): Terrosa, teriparatide, Osteoporosis, 04/01/2017, Additional monitoring, Biosimilar, 6, Authorised
23/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Idefirix, Imlifidase, PM: decision on the application for modification of an agreed PIP, P/0076/2022
23/03/2023 Agenda: Agenda of the CAT meeting 22-23 March 2023
23/03/2023 National registers of authorised medicines
23/03/2023 Periodic safety update single assessment: Clindamycin phosphate / tretinoin : List of nationally authorised medicinal products - PSUSA/00010080/202207
22/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Piqray, Alpelisib, PM: decision on the application for modification of an agreed PIP, P/0536/2021
22/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Adakveo, Crizanlizumab, PM: decision on the application for modification of an agreed PIP, P/0533/2021
22/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Biktarvy, bictegravir,emtricitabine,tenofovir alafenamide, PM: decision on the application for modification of an agreed PIP, P/0528/2021
22/03/2023 Human medicines European public assessment report (EPAR): Kadcyla, trastuzumab emtansine, Breast Neoplasms, 15/11/2013, 15, Authorised
22/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Juluca, rilpivirine,dolutegravir, PM: decision on the application for modification of an agreed PIP, P/0524/2021
22/03/2023 Clinical Trials Information System (CTIS) bitesize talk: Document and personal data in CTIS , Online, 14:30 - 16:00 Amsterdam time (CET), from 23/02/2023 to 23/02/2023
22/03/2023 Human medicines European public assessment report (EPAR): Polivy, polatuzumab vedotin, Lymphoma, B-Cell, 16/01/2020, Orphan, Additional monitoring, Conditional approval, 5, Authorised
22/03/2023 Other: Rules for reimbursement of expenses for delegates attending meetings with effect from 17 March 2023
22/03/2023 Human medicines European public assessment report (EPAR): Elebrato Ellipta, fluticasone furoate, umeclidinium bromide, vilanterol trifenatate, Pulmonary Disease, Chronic Obstructive, 15/11/2017, 11, Authorised
22/03/2023 Human medicines European public assessment report (EPAR): Suliqua, insulin glargine, lixisenatide, Diabetes Mellitus, Type 2, 11/01/2017, 10, Authorised
22/03/2023 Human medicines European public assessment report (EPAR): Trelegy Ellipta, fluticasone furoate, umeclidinium bromide, vilanterol trifenatate, Pulmonary Disease, Chronic Obstructive, 15/11/2017, 10, Authorised
22/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): (Z)-N-(3-bromo-4- fluorophenyl)-N-hydroxy-4-(2-(sulfamoylamino)ethylamino)-1,2,5-oxadiazole-3-carboximidamide, PM: decision on the application for modification of an agreed PIP, P/0246/2018
22/03/2023 Template or form: QRD Appendix I - Adverse event (PhV) MSs reporting details
22/03/2023 Human medicines European public assessment report (EPAR): Pradaxa, Dabigatran etexilate mesilate, Arthroplasty, Replacement; Venous Thromboembolism, 17/03/2008, 39, Authorised
22/03/2023 Human medicines European public assessment report (EPAR): Hexacima, hepatitis B surface antigen, Diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens Pertussis Toxoid Filamentous Haemagglutinin, poliovirus (inactivated) type 1 (Mahoney) type 2 (MEF-1) type 3 (Saukett), Haemophilus influenzae type b polysaccharide (Polyribosylribitol Phosphate) conjugated to Tetanus protein, Hepatitis B; Tetanus; Immunization; Meningitis, Haemophilus; Whooping Cough; Poliomyelitis; Diphtheria, 17/04/2013, 22/02/2013, 28, Authorised
22/03/2023 Human medicines European public assessment report (EPAR): NovoRapid, insulin aspart, Diabetes Mellitus, 07/09/1999, 32, Authorised
22/03/2023 Human medicines European public assessment report (EPAR): Xolair, omalizumab, Asthma; Urticaria, 25/10/2005, 45, Authorised
22/03/2023 Human medicines European public assessment report (EPAR): Hexyon, filamentous haemagglutinin, Haemophilus influenzae type B polysaccharide (polyribosylribitol phosphate), hepatitis B surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (Mahoney strain) produced on Vero cells, poliovirus (inactivated) type 2 (MEF-1 strain) produced on Vero cells, poliovirus (inactivated) type 3 (Saukett strain) produced on Vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, Diphtheria toxoid, Hepatitis B; Tetanus; Immunization; Meningitis, Haemophilus; Whooping Cough; Poliomyelitis; Diphtheria, 17/04/2013, 22/02/2013, 29, Authorised
22/03/2023 Other: Contact details of national competent authorities for requests of translation exemptions falling under Art. 63.3 of Directive 2001/83/EC and cases of shortages
22/03/2023 News and press releases: Advancing regulatory science in the EU – mid-point report published
22/03/2023 Human medicines European public assessment report (EPAR): Darzalex, Daratumumab, Multiple Myeloma, 20/05/2016, Orphan, Accelerated assessment, 20, Authorised
22/03/2023 Periodic safety update single assessment: Diltiazem - CMDh Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation - PSUSA/00001084/202205
22/03/2023 Periodic safety update single assessment: Diltiazem - List of nationally authorised medicinal products - PSUSA/00001084/202205
22/03/2023 Human medicines European public assessment report (EPAR): Keppra, levetiracetam, Epilepsy, 29/09/2000, 53, Authorised
22/03/2023 Human medicines European public assessment report (EPAR): Insulin lispro Sanofi, insulin lispro, Diabetes Mellitus, 19/07/2017, Biosimilar, 8, Authorised
22/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Vamorolone, PM: decision on the application for modification of an agreed PIP, P/0515/2021
22/03/2023 Human medicines European public assessment report (EPAR): Noxafil, posaconazole, Candidiasis; Mycoses; Coccidioidomycosis; Aspergillosis, 25/10/2005, 36, Authorised
22/03/2023 Human medicines European public assessment report (EPAR): Ultomiris, ravulizumab, Hemoglobinuria, Paroxysmal, 02/07/2019, Additional monitoring, 10, Authorised
22/03/2023 Human medicines European public assessment report (EPAR): Imcivree, Setmelanotide, Obesity, 16/07/2021, Orphan, Additional monitoring, 7, Authorised
22/03/2023 Human medicines European public assessment report (EPAR): Synagis, palivizumab, Respiratory Syncytial Virus Infections, 13/08/1999, 45, Authorised
22/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Evkeeza, Evinacumab, PM: decision on the application for modification of an agreed PIP, P/0514/2021
22/03/2023 Enpr-EMA Coordinating Group meeting , Online, 15:00 - 16:30 Amsterdam time (CET), from 15/02/2023 to 15/02/2023
21/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, PM: decision on the application for modification of an agreed PIP, P/0510/2021
21/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Molgramostim, PM: decision on the application for modification of an agreed PIP, P/0509/2021
21/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Plegridy, peginterferon beta-1a, PM: decision on the application for modification of an agreed PIP, P/0359/2022
21/03/2023 Report: 2022 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission
21/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Dovprela (previously Pretomanid FGK), Pretomanid, PM: decision on the application for modification of an agreed PIP, P/0507/2021
21/03/2023 Human medicines European public assessment report (EPAR): MicardisPlus, Telmisartan, hydrochlorothiazide, Hypertension, 19/04/2002, 33, Authorised
21/03/2023 Human medicines European public assessment report (EPAR): Lamivudine/Zidovudine Teva, lamivudine, zidovudine, HIV Infections, 28/02/2011, Generic, 16, Withdrawn
21/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Cotadutide, PM: decision on the application for modification of an agreed PIP, P/0506/2021
21/03/2023 Report: 2022 European Medicines Agency annual report on independence
21/03/2023 Human medicines European public assessment report (EPAR): Vihuma, simoctocog alfa, Hemophilia A, 13/02/2017, Additional monitoring, 8, Authorised
21/03/2023 Human medicines European public assessment report (EPAR): Nuwiq, simoctocog alfa, Hemophilia A, 22/07/2014, 13, Authorised
21/03/2023 Human medicines European public assessment report (EPAR): Elocta, efmoroctocog alfa, Hemophilia A, 18/11/2015, 12, Authorised
21/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Lumasiran (ALN-GO1), PM: decision on the application for modification of an agreed PIP, P/0505/2021
21/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine hydrochloride, PM: decision on the application for modification of an agreed PIP, P/0502/2021
21/03/2023 Human medicines European public assessment report (EPAR): Inrebic, fedratinib dihydrochloride monohydrate, Myeloproliferative Disorders; Primary Myelofibrosis, 08/02/2021, Orphan, Additional monitoring, 4, Authorised
21/03/2023 Human medicines European public assessment report (EPAR): Revatio, sildenafil, Hypertension, Pulmonary, 28/10/2005, 49, Authorised
21/03/2023 Human medicines European public assessment report (EPAR): Symtuza, darunavir, cobicistat, emtricitabine, tenofovir alafenamide, HIV Infections, 21/09/2017, 17, Authorised
21/03/2023 Human medicines European public assessment report (EPAR): Ecalta, anidulafungin, Candidiasis, 20/09/2007, 24, Authorised
21/03/2023 Orphan designation: Recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB linked to the human IgG1 Fc domain (luspatercept) for the: Treatment of beta thalassaemia intermedia and major, 29/07/2014, Positive
21/03/2023 Human medicines European public assessment report (EPAR): Nevirapine Teva, nevirapine, HIV Infections, 30/11/2009, Generic, 11, Withdrawn
21/03/2023 Periodic safety update single assessment: Ethinylestradiol / norethisterone : List of nationally authorised medicinal products - PSUSA/00001312/202208
21/03/2023 Periodic safety update single assessment: Alprostadil (indicated in peripheral arterial occlusive diseases) - List of nationally authorised medicinal products - PSUSA/00000111/202207
21/03/2023 EPAR - Public assessment report: Nevirapine Teva : EPAR - Public assessment report
20/03/2023 Human medicines European public assessment report (EPAR): Aldara, imiquimod, Condylomata Acuminata; Keratosis; Keratosis, Actinic; Carcinoma, Basal Cell, 18/09/1998, 30, Authorised
20/03/2023 Human medicines European public assessment report (EPAR): Alkindi, hydrocortisone, Adrenal Insufficiency, 09/02/2018, 8, Authorised
20/03/2023 Human medicines European public assessment report (EPAR): Zomarist, vildagliptin, metformin hydrochloride, Diabetes Mellitus, Type 2, 30/11/2008, 23, Authorised
20/03/2023 Human medicines European public assessment report (EPAR): Mircera, Methoxy polyethylene glycol-epoetin beta, Anemia; Kidney Failure, Chronic, 20/07/2007, 28, Authorised
20/03/2023 Human medicines European public assessment report (EPAR): Erivedge, vismodegib, Carcinoma, Basal Cell, 12/07/2013, 26/04/2013, 15, Authorised
20/03/2023 Clinical Trials Information System (CTIS): Walk-in clinic - December 2023 , Online, 16:00 - 17:00 Amsterdam time (CET), from 13/12/2023 to 13/12/2023
20/03/2023 Clinical Trials Information System (CTIS): Walk-in clinic - October 2023 , Online, 16:00 - 17:00 Amsterdam time (CEST), from 10/10/2023 to 10/10/2023
20/03/2023 Clinical Trials Information System (CTIS): Walk-in clinic - November 2023 , Online, 16:00 - 17:00 Amsterdam time (CET), from 15/11/2023 to 15/11/2023
20/03/2023 Periodic safety update single assessment: Beclometasone formoterol (inhalative application) - List of nationally authorised medicinal products - PSUSA/00010068/202207
20/03/2023 Clinical Trials Information System (CTIS): Walk-in clinic - June 2023 , Online, 16:00 - 17:00 Amsterdam time (CEST), from 14/06/2023 to 14/06/2023
20/03/2023 Clinical Trials Information System (CTIS): Walk-in clinic - July 2023 , Online, 16:00 - 17:00 Amsterdam time (CEST), from 19/07/2023 to 19/07/2023
20/03/2023 Clinical Trials Information System (CTIS): Walk-in clinic - August 2023 , Online, 16:00 - 17:00 Amsterdam time (CEST), from 23/08/2023 to 23/08/2023